Related Experiment Videos
[Hirudin and hirudin fragments]
1Laboratoire Central d'Hématologie, Hôpital Rothschild, Paris.
Annales De Cardiologie Et D'Angeiologie
|October 1, 1992
Summary
Recombinant hirudin and its analogs offer direct thrombin inhibition, showing good tolerability and efficacy. These agents are suitable for situations where thrombin plays a key role or heparin therapy is insufficient.
Area of Science:
- Biochemistry
- Pharmacology
- Hematology
Context:
- Hirudin is a direct and specific thrombin inhibitor, unlike heparin which requires cofactors.
- Recombinant hirudin demonstrates favorable pharmacokinetics and tolerability in preclinical and healthy volunteer studies.
- Hirudin analogs, including bivalent Hirulogs, exhibit similar properties and have shown efficacy in thrombosis models.
Purpose:
- To evaluate the efficacy and safety profile of hirudin and its derivatives as anticoagulants.
- To compare the mechanism of action and therapeutic potential of hirudin-based agents versus heparin.
- To identify optimal clinical applications for hirudin and its analogs.
Summary:
- Hirudin directly inhibits thrombin without needing plasma cofactors, offering a distinct advantage over heparin.
- Recombinant hirudin has a clearance half-life of 1-2 hours (IV) and 75% bioavailability (SC), with a satisfactory efficacy-to-safety ratio in experimental models.
- Bivalent hirudin derivatives (Hirulogs) share similar pharmacological properties and have proven effective in various thrombosis models and human studies.
Impact:
- Hirudin and its derivatives present a promising alternative or adjunct to heparin therapy.
- These agents are particularly relevant for clinical scenarios involving significant thrombin activity or heparin resistance.
- The direct inhibition mechanism and favorable safety profile support their potential in managing thrombotic disorders.